Preferences for schizophrenia treatment outcomes among public policy makers, consumers, families, and providers

Martha Shumway, Teri Saunders, David Shern, Emily Pines, Amy Downs, Tracy Burbine, James Beller

Research output: Contribution to journalArticle

Abstract

Objective: This study measured state public policy makers' ratings of the importance of several key schizophrenia treatment outcomes and compared them with the ratings of primary stakeholders in schizophrenia treatment. Methods: Three groups of policy makers (40 administrative decision makers, 40 state legislators, and 20 legislative aides) and three groups of core stakeholders (20 persons with schizophrenia, 13 of their family members, and 20 of their mental health care providers) were recruited in Florida. Participants rated 12 descriptions of schizophrenia-related health states that reflected better and worse outcomes in six domains: psychotic symptoms, deficit symptoms, medication side effects, productive activity, daily activity, and social activity. Results: All participants valued functional outcomes, such as improved productive and social activity, more than they valued improvements in symptoms. Public policy makers and primary stakeholders differed in the value they placed on two of the six outcomes. Compared with primary stakeholders, policy makers valued improvements in social functioning significantly more and improvements in medication side effects significantly less. Conclusions: Policy makers and primary stakeholders place similar value on some of the major goals of schizophrenia treatment, with both groups valuing functional outcomes most highly. However, the difference between groups in the importance placed on medication side effects may lead to conflicts in the allocation of resources to the provision of newer and more expensive medications, which are associated with fewer side effects. This initial examination of policy makers' views provides a starting point for developing consensus about schizophrenia treatment policies.

Original languageEnglish (US)
Pages (from-to)1124-1128
Number of pages5
JournalPsychiatric Services
Volume54
Issue number8
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Public Policy
schizophrenia
Administrative Personnel
Schizophrenia
public policy
stakeholder
medication
Group
rating
Resource Allocation
Health Personnel
family member
decision maker
Values
Consensus
Mental Health
deficit
Therapeutics
mental health
health care

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Public Health, Environmental and Occupational Health
  • Health(social science)
  • Health Professions(all)

Cite this

Shumway, M., Saunders, T., Shern, D., Pines, E., Downs, A., Burbine, T., & Beller, J. (2003). Preferences for schizophrenia treatment outcomes among public policy makers, consumers, families, and providers. Psychiatric Services, 54(8), 1124-1128. https://doi.org/10.1176/appi.ps.54.8.1124

Preferences for schizophrenia treatment outcomes among public policy makers, consumers, families, and providers. / Shumway, Martha; Saunders, Teri; Shern, David; Pines, Emily; Downs, Amy; Burbine, Tracy; Beller, James.

In: Psychiatric Services, Vol. 54, No. 8, 01.08.2003, p. 1124-1128.

Research output: Contribution to journalArticle

Shumway, M, Saunders, T, Shern, D, Pines, E, Downs, A, Burbine, T & Beller, J 2003, 'Preferences for schizophrenia treatment outcomes among public policy makers, consumers, families, and providers', Psychiatric Services, vol. 54, no. 8, pp. 1124-1128. https://doi.org/10.1176/appi.ps.54.8.1124
Shumway, Martha ; Saunders, Teri ; Shern, David ; Pines, Emily ; Downs, Amy ; Burbine, Tracy ; Beller, James. / Preferences for schizophrenia treatment outcomes among public policy makers, consumers, families, and providers. In: Psychiatric Services. 2003 ; Vol. 54, No. 8. pp. 1124-1128.
@article{9c67a348a7504358880dd9a1b1776863,
title = "Preferences for schizophrenia treatment outcomes among public policy makers, consumers, families, and providers",
abstract = "Objective: This study measured state public policy makers' ratings of the importance of several key schizophrenia treatment outcomes and compared them with the ratings of primary stakeholders in schizophrenia treatment. Methods: Three groups of policy makers (40 administrative decision makers, 40 state legislators, and 20 legislative aides) and three groups of core stakeholders (20 persons with schizophrenia, 13 of their family members, and 20 of their mental health care providers) were recruited in Florida. Participants rated 12 descriptions of schizophrenia-related health states that reflected better and worse outcomes in six domains: psychotic symptoms, deficit symptoms, medication side effects, productive activity, daily activity, and social activity. Results: All participants valued functional outcomes, such as improved productive and social activity, more than they valued improvements in symptoms. Public policy makers and primary stakeholders differed in the value they placed on two of the six outcomes. Compared with primary stakeholders, policy makers valued improvements in social functioning significantly more and improvements in medication side effects significantly less. Conclusions: Policy makers and primary stakeholders place similar value on some of the major goals of schizophrenia treatment, with both groups valuing functional outcomes most highly. However, the difference between groups in the importance placed on medication side effects may lead to conflicts in the allocation of resources to the provision of newer and more expensive medications, which are associated with fewer side effects. This initial examination of policy makers' views provides a starting point for developing consensus about schizophrenia treatment policies.",
author = "Martha Shumway and Teri Saunders and David Shern and Emily Pines and Amy Downs and Tracy Burbine and James Beller",
year = "2003",
month = "8",
day = "1",
doi = "10.1176/appi.ps.54.8.1124",
language = "English (US)",
volume = "54",
pages = "1124--1128",
journal = "Psychiatric Services",
issn = "1075-2730",
publisher = "American Psychiatric Association",
number = "8",

}

TY - JOUR

T1 - Preferences for schizophrenia treatment outcomes among public policy makers, consumers, families, and providers

AU - Shumway, Martha

AU - Saunders, Teri

AU - Shern, David

AU - Pines, Emily

AU - Downs, Amy

AU - Burbine, Tracy

AU - Beller, James

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Objective: This study measured state public policy makers' ratings of the importance of several key schizophrenia treatment outcomes and compared them with the ratings of primary stakeholders in schizophrenia treatment. Methods: Three groups of policy makers (40 administrative decision makers, 40 state legislators, and 20 legislative aides) and three groups of core stakeholders (20 persons with schizophrenia, 13 of their family members, and 20 of their mental health care providers) were recruited in Florida. Participants rated 12 descriptions of schizophrenia-related health states that reflected better and worse outcomes in six domains: psychotic symptoms, deficit symptoms, medication side effects, productive activity, daily activity, and social activity. Results: All participants valued functional outcomes, such as improved productive and social activity, more than they valued improvements in symptoms. Public policy makers and primary stakeholders differed in the value they placed on two of the six outcomes. Compared with primary stakeholders, policy makers valued improvements in social functioning significantly more and improvements in medication side effects significantly less. Conclusions: Policy makers and primary stakeholders place similar value on some of the major goals of schizophrenia treatment, with both groups valuing functional outcomes most highly. However, the difference between groups in the importance placed on medication side effects may lead to conflicts in the allocation of resources to the provision of newer and more expensive medications, which are associated with fewer side effects. This initial examination of policy makers' views provides a starting point for developing consensus about schizophrenia treatment policies.

AB - Objective: This study measured state public policy makers' ratings of the importance of several key schizophrenia treatment outcomes and compared them with the ratings of primary stakeholders in schizophrenia treatment. Methods: Three groups of policy makers (40 administrative decision makers, 40 state legislators, and 20 legislative aides) and three groups of core stakeholders (20 persons with schizophrenia, 13 of their family members, and 20 of their mental health care providers) were recruited in Florida. Participants rated 12 descriptions of schizophrenia-related health states that reflected better and worse outcomes in six domains: psychotic symptoms, deficit symptoms, medication side effects, productive activity, daily activity, and social activity. Results: All participants valued functional outcomes, such as improved productive and social activity, more than they valued improvements in symptoms. Public policy makers and primary stakeholders differed in the value they placed on two of the six outcomes. Compared with primary stakeholders, policy makers valued improvements in social functioning significantly more and improvements in medication side effects significantly less. Conclusions: Policy makers and primary stakeholders place similar value on some of the major goals of schizophrenia treatment, with both groups valuing functional outcomes most highly. However, the difference between groups in the importance placed on medication side effects may lead to conflicts in the allocation of resources to the provision of newer and more expensive medications, which are associated with fewer side effects. This initial examination of policy makers' views provides a starting point for developing consensus about schizophrenia treatment policies.

UR - http://www.scopus.com/inward/record.url?scp=0042130050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042130050&partnerID=8YFLogxK

U2 - 10.1176/appi.ps.54.8.1124

DO - 10.1176/appi.ps.54.8.1124

M3 - Article

C2 - 12883140

AN - SCOPUS:0042130050

VL - 54

SP - 1124

EP - 1128

JO - Psychiatric Services

JF - Psychiatric Services

SN - 1075-2730

IS - 8

ER -